EA200870538A1 - Лиофилизированные композиции анти-egfr антител - Google Patents

Лиофилизированные композиции анти-egfr антител

Info

Publication number
EA200870538A1
EA200870538A1 EA200870538A EA200870538A EA200870538A1 EA 200870538 A1 EA200870538 A1 EA 200870538A1 EA 200870538 A EA200870538 A EA 200870538A EA 200870538 A EA200870538 A EA 200870538A EA 200870538 A1 EA200870538 A1 EA 200870538A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lyophylized
egfr antibodies
compositions anti
provides
present
Prior art date
Application number
EA200870538A
Other languages
English (en)
Inventor
Меера Агаркхед
Арвинд Сривастава
Джоел Голдстейн
Original Assignee
Имклоун Системз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Системз Инкорпорейтед filed Critical Имклоун Системз Инкорпорейтед
Publication of EA200870538A1 publication Critical patent/EA200870538A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

В одном варианте осуществления настоящее изобретение представляет устойчивую лиофилизированную композицию, включающую анти-EGFR антитело, предпочтительно цетуксимаб; лактобионовую кислоту; и буфер, предпочтительно гистидин. В одном предпочтительном варианте осуществления настоящее изобретение представляет устойчивую лиофилизированную композицию, включающую от приблизительно 50 до приблизительно 140 мг/мл ERBITUX®, приблизительно 0,125% лактобионовой кислоты, приблизительно 25 мМ гистидинового буфера при рН приблизительно 6,0, приблизительно 0,005% Tween 80 и приблизительно 1,875% глицина.
EA200870538A 2006-06-14 2007-06-13 Лиофилизированные композиции анти-egfr антител EA200870538A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14
PCT/US2007/071119 WO2007147001A2 (en) 2006-06-14 2007-06-13 Lyophilized formulations of anti-egfr antibodies

Publications (1)

Publication Number Publication Date
EA200870538A1 true EA200870538A1 (ru) 2009-04-28

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870538A EA200870538A1 (ru) 2006-06-14 2007-06-13 Лиофилизированные композиции анти-egfr антител

Country Status (18)

Country Link
US (1) US20100158925A1 (ru)
EP (1) EP2029163A4 (ru)
JP (1) JP2009540015A (ru)
KR (1) KR20090021298A (ru)
CN (1) CN101466404A (ru)
AU (1) AU2007260769A1 (ru)
BR (1) BRPI0713421A2 (ru)
CA (1) CA2654794A1 (ru)
CR (1) CR10493A (ru)
EA (1) EA200870538A1 (ru)
EC (1) ECSP088962A (ru)
IL (1) IL195794A0 (ru)
MA (1) MA30515B1 (ru)
MX (1) MX2008015852A (ru)
NO (1) NO20085131L (ru)
TN (1) TNSN08511A1 (ru)
WO (1) WO2007147001A2 (ru)
ZA (1) ZA200810456B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
DK2993186T3 (da) 2008-03-14 2019-11-25 Biocon Ltd En monoklonal antistof og en fremgangsmåde hertil
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011061712A1 (en) * 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CA2783715A1 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
JP6294075B2 (ja) 2010-05-28 2018-03-14 ノヴォ ノルディスク アー／エス 抗体及び防腐剤を含む安定した多用量組成物
SG186421A1 (en) * 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
DK3024485T3 (da) 2013-07-23 2020-12-07 Biocon Ltd Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
RS63152B1 (sr) 2013-07-25 2022-05-31 Cytomx Therapeutics Inc Multispecifična antitela, multispecifična antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
AU2014318545A1 (en) * 2013-09-12 2016-03-24 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CN113512120A (zh) * 2014-12-22 2021-10-19 西雅图免疫公司 双特异性四价抗体及其制造和使用方法
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
EP3563863B1 (en) * 2016-12-28 2023-07-12 JCR Pharmaceuticals Co., Ltd. Lyophilized preparation
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
CA3100981A1 (en) * 2018-06-01 2019-12-05 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
EP3917618A1 (en) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
JP2022535924A (ja) * 2019-06-06 2022-08-10 ジャナックス セラピューティクス，インク． 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
AU2021326469A1 (en) 2020-08-11 2023-04-06 Janux Therapeutics, Inc. Cleavable linker compositions and methods
JP2023552812A (ja) 2020-12-09 2023-12-19 ジャナックス セラピューティクス，インク． Ｐｓｍａおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
WO2023056485A1 (en) * 2021-10-03 2023-04-06 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CA2642270A1 (en) * 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation

Also Published As

Publication number Publication date
BRPI0713421A2 (pt) 2012-03-13
AU2007260769A1 (en) 2007-12-21
MA30515B1 (fr) 2009-06-01
ZA200810456B (en) 2009-12-30
EP2029163A4 (en) 2010-08-11
EP2029163A2 (en) 2009-03-04
WO2007147001A2 (en) 2007-12-21
CA2654794A1 (en) 2007-12-21
CN101466404A (zh) 2009-06-24
CR10493A (es) 2009-02-26
KR20090021298A (ko) 2009-03-02
TNSN08511A1 (en) 2010-04-14
NO20085131L (no) 2009-03-13
IL195794A0 (en) 2011-08-01
US20100158925A1 (en) 2010-06-24
MX2008015852A (es) 2009-02-23
JP2009540015A (ja) 2009-11-19
WO2007147001A3 (en) 2008-07-10
ECSP088962A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
EA200970880A1 (ru) Стабильные композиции на основе антител
EA201400933A1 (ru) Агенты, связывающие склеростин
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MY146100A (en) Antibody formulations
EA200700136A1 (ru) Анти-cd154-антитела
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
MY174493A (en) Binding agents
RU2013137740A (ru) Жидкая композиция, содержащая антитело высокой концентрации
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
CO5720212A1 (es) Composicion de anticuerpo her2
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
WO2008121615A3 (en) Antibody formulation
ATE534667T1 (de) Anti-abeta antikörper
EP1855719A4 (en) NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME
EA200800601A1 (ru) Связывающие fas антитела
RU2007133599A (ru) Композиции антител против ctla-4
DOP2005000210A (es) Antibony formulations
TH92463A (th) สูตรผสมแอนติบอดีที่เสถียร
PE20090767A1 (es) Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion
TH84864B (th) สูตรแอนติบอดี
TH84864A (th) สูตรแอนติบอดี